| Genmab A/S | 2,148.00 / +2.19% |
| Date/Time | 04/13 / 16:59 |
| Chg. / Chg.(%) | 46.00 / +2.19% |
| Bid | 2,154.00 / 152 |
| Ask | 2,156.00 / 108 |
| Open | 2,105.00 |
| Previous Close | 2,102.00 |
| High | 2,168.00 |
| Low | 2,105.00 |
| Volume [DKK] | 300,287,522.00 |
| Volume [Units] | 146,072 |
| Price fixings | 5482 |
| ISIN | DK0010272202 |
| Security | GMAB |
| Exchange | OMX Nordic |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| OMX Nordic | 2,148.00 |  |
146,072 |
| Cboe Europe .. | 2,148.00 | |
19,031 |
| Turquoise | 2,155.00 | |
13,886 |
| London Inter.. | 2,148.5 | |
8,895 |
| Cboe Europe .. | 2,163.50 | |
1,272 |
| Cboe Europe .. | 2,145.00 | |
533 |
| Nasdaq Other.. | 342.5800 | |
378 |
| Frankfurt | 288.2000 | |
203 |
| Stuttgart | 284.800 |  |
177 |
| TradeGate | 290.200 | |
74 |
| gettex | 289.900 | |
12 |
| Vienna Globa.. | 289.40 | |
0 |
| München | 286.00 | |
0 |
| Düsseldorf | 287.80 | |
0 |
| Berlin | 288.70 | |
0 |
| Lang & Schwa.. | 289.10 | |
|
| Mexico | 7,638.15 |  |
11,330 |
News
- Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
04/09/2021 / 22:00 - GlobeNewswire - Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
04/01/2021 / 12:45 - GlobeNewswire - Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents
03/31/2021 / 12:45 - GlobeNewswire - BioNTech Announces Full Year 2020 Financial Results and Corporate Update
03/30/2021 / 12:30 - GlobeNewswire - Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
03/30/2021 / 07:21 - GlobeNewswire
Real-time